REG - Ondine Biomedical - Grant of Options

Ondine BiomedicalAnnouncement

26/02/2025 08:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250226:nRSZ4439Ya&default-theme=true

RNS Number : 4439Y  Ondine Biomedical Inc.  26 February 2025

26 February 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Grant of Options

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering
light-activated antimicrobial treatments, announces the grant of stock options
to two key executives as part of the Company's ongoing commitment to
attracting and retaining top-tier leadership.

On 25 February 2025, Ondine awarded a total of 9,315,286 options to subscribe
for new common shares in the Company ("Options") to Dr. Nicolas Lobel, in
recognition of his significant contributions to the development and
advancement of Ondine's cutting-edge photodisinfection technology, and to
Michael Behlke as part of his long-term compensation package. Details of the
Options are as follows:

 Director            Position                                                      Options granted  Exercise price  Total options now held
 Dr. Nicolas Loebel  President & Chief Technology Officer                          6,000,000        11.25 pence     9,575,000
 Michael Behlke      Chief Financial Officer & Chief Operating Officer (PDMR)      3,315,286        11.25 pence     3,315,286

The Options all have an exercise price of 11.25 pence, being the closing share
price on 21 February 2025 (the "Approval Date"), the day on which the grant of
Options was approved by the Board. The Options vest evenly over a period of 3
years from the Grant Date, with a third vesting on each of the three
successive anniversaries of the Grant Date, and can be exercised for a period
of eight years from the Grant Date.

Following the grant of Options, the Company has 22,420,286 options to
subscribe for new common shares outstanding, which represents 5.07% of the
Company's current issued share capital.

The FCA notifications in respect of the above Option grants, made in
accordance with the requirements of the UK Market Abuse Regulations, are
appended below.

Carolyn Cross, Ondine's Chief Executive Officer, commented:

"We are pleased to recognize the dedication and expertise of our leadership
team. These option grants mark a key step in aligning leadership incentives
with Ondine's long-term success.

"As we continue to expand our global footprint and advance our breakthrough
infection prevention solutions, these options serve as a reflection of our
commitment to driving shareholder value and attracting and retaining top
talent."

The newly granted stock options will vest over 3 years, ensuring continued
alignment with the Company's strategic objectives and long-term growth plans.

Enquiries, please contact:

 Ondine Biomedical Inc.                                      www.ondinebio.com (https://ondinebio.com/)
 Carolyn Cross, CEO                                          Via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Rupert Walford, Kathryn Deegan                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada and several other countries under the name Steriwave(®).
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

  1.     Details of the person discharging managerial responsibilities / person closely
         associated
 a)      Name                                                         1.    Nicolas Lobel

                                                                      2.    Michael Behlke
 2.      Reason for the Notification
 a)      Position/status                                              1.     President and CTO (PDMR)

                                                                      2.     CFO and COO (PDMR)
 b)      Initial notification/Amendment                               Initial notification
 3.      Details of the issuer, emission allowance market participant, auction
         platform, auctioneer or auction monitor
 a)      Name                                                         Ondine Biomedical Inc.
 b)      LEI                                                          9845005B69E07CGF4A56
 4.      Details of the transaction(s): section to be repeated for (i) each type of
         instrument; (ii) each type of transaction; (iii) each date; and (iv) each
         place where transactions have been conducted
 a)      Description of the Financial instrument, type of instrument  Options to subscribe for Common Shares

         Identification code                                          ISIN: CA68234M2058
 b)      Nature of the transaction                                    Grant of options to subscribe for common shares of no par value
 c)      Price(s) and volume(s)                                       PDMR            Price(s)                                   Volume(s)
                                                                      Nicolas Lobel   Exercise price of 11.25 pence per share    6,000,000
                                                                      Michael Behlke  Exercise price of 11.25 pence per share    3,315,286
 d)      Aggregated information:                                      N/A

         ·Aggregated volume

         ·Price
 e)      Date of the transaction                                      25 February 2025
 f)      Place of the transaction                                     Outside a trading venue

d)

Aggregated information:

·Aggregated volume

·Price

N/A

 

e)

Date of the transaction

25 February 2025

f)

Place of the transaction

Outside a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSELFAIEISELE